<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 6, 2018 (HealthDay News) — The lifetime risks of Alzheimer’s disease (AD) dementia vary considerably by age, gender, and the preclinical or clinical disease state, according to a study published online May 22 in Alzheimer’s & Dementia<\/i>.<\/p>\n
Ron Brookmeyer, Ph.D., and Nada Abdalla, from the University of California in Los Angeles, used a multistate model for the disease process together with U.S. death rates to estimate the lifetime and 10-year risks of AD dementia.<\/p>\n
The researchers found that there was considerable variation in lifetime risks of AD by age, gender, and the preclinical or clinical disease state of the individual. For a female with only amyloidosis, the lifetime risks were 8.4 and 29.3 percent for a 90- and 65-year-old, respectively. Lifetime risks of AD dementia greater than 50 percent were seen for persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration.<\/p>\n
“Most persons with preclinical AD will not develop AD dementia during their lifetimes,” the authors write. “Lifetime risks help interpret the clinical significance of biomarker screening tests for AD.”<\/p>\n
One author disclosed financial ties to Takeda.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n